

## **Gambro introduces FleXitrate — the complete citrate-calcium offering for Continuous Renal Replacement Therapy (CRRT)**

**Effective CRRT is largely determined by adequate anticoagulation of the extracorporeal circuit. With FleXitrate, Gambro makes performing regional citrate anticoagulation simple and safe.**

FleXitrate is enabled by Prismaflex eXeed II, Gambro's latest software improvement to the Prismaflex system. The Prismaflex eXeed II allows convective and diffusive therapies with fully integrated citrate management and calcium substitution to the patient.

In addition to integrated calcium management, FleXitrate includes Gambro's full range of pre-formulated citrate anticoagulant solutions and calcium-free dialysis solutions for easier citrate implementation.

"FleXitrate brings together the flexibility of Prismaflex eXeed II with the complete line of Gambro solutions," says William Clark, M.D. Vice President of Medical Strategy and Therapy Development at Gambro. "We are now offering customers a simple and cost-effective way to deliver regional citrate anticoagulation."

***For further information please contact:***

*Maria Lundbäck, Director External Communications, +46 705 136534*

---

*Gambro is a global medical technology company and a leader in developing, manufacturing and supplying products, therapies and services for In-center Care and Self-care hemodialysis, Peritoneal Dialysis, Renal Intensive Care and Hepatic Care. Gambro was founded in 1964 and has more than 8,000 employees, production facilities in 9 countries, sales subsidiaries in more than 40 and sales in more than 100 countries.*

**Gambro**  
14143 Denver West Parkway  
Lakewood, CO 80401  
Tel 800-525-2623  
[www.gambro.com](http://www.gambro.com)